Significance The global outbreak of COVID-19 infections generated an unprecedented need to develop novel therapeutic strategies. The SARS-CoV-2 virus enters host cells after binding to the angiotensin-converting enzyme 2 (ACE2), but whether renin−angiotensin−aldosterone system inhibitors (RAASi) are beneficial remains controversial. Standard statistical approaches may fail in assessing medications effects, due to multiple sources of bias in COVID-19 case series collected on an emergency basis. We present a data-driven approach to tackle these challenges. Multilayer risk stratifications were derived for assessing drugs effect, while Bayesian networks were estimated, to analyze dependencies among risk factors’ and treatments’ impact on survival. We provide strong evidence for protectivity of RAASi on hospitalized patients that call for randomized controlled trials of RAASi as COVID-19 treatment option. As the COVID-19 pandemic is spreading around the world, increasing evidence highlights the role of cardiometabolic risk factors in determining the susceptibility to the disease. The fragmented data collected during the initial emergency limited the possibility of investigating the effect of highly correlated covariates and of modeling the interplay between risk factors and medication. The present study is based on comprehensive monitoring of 576 COVID-19 patients. Different statistical approaches were applied to gain a comprehensive insight in terms of both the identification of risk factors and the analysis of dependency structure among clinical and demographic characteristics. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus enters host cells by binding to the angiotensin-converting enzyme 2 (ACE2), but whether or not renin−angiotensin−aldosterone system inhibitors (RAASi) would be beneficial to COVID-19 cases remains controversial. The survival tree approach was applied to define a multilayer risk stratification and better profile patient survival with respect to drug regimens, showing a significant protective effect of RAASi with a reduced risk of in-hospital death. Bayesian networks were estimated, to uncover complex interrelationships and confounding effects. The results confirmed the role of RAASi in reducing the risk of death in COVID-19 patients. De novo treatment with RAASi in patients hospitalized with COVID-19 should be prospectively investigated in a randomized controlled trial to ascertain the extent of risk reduction for in-hospital death in COVID-19.
【저자키워드】 COVID-19, RAAS, survival tree, Bayesian network, 【초록키워드】 Randomized controlled trial, Treatment, SARS-CoV-2, ACE2, coronavirus, Risk factors, Randomized controlled trials, susceptibility, COVID-19 pandemic, risk, SARS-CoV-2 virus, drug, hospitalized patients, risk factor, severe acute respiratory syndrome Coronavirus, virus, angiotensin-converting enzyme 2, risk stratification, survival, COVID-19 infection, outbreak, Therapeutic strategies, respiratory, medication, inhibitor, Cardiometabolic risk factors, COVID-19 patients, protective effect, binding, Bayesian networks, Angiotensin-converting enzyme, cardiometabolic, Evidence, Analysis, angiotensin, RAASi, COVID-19 cases, Standard, demographic characteristics, host cells, host cell, In-hospital death, risk of death, acute respiratory syndrome, patient survival, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, reduced risk, COVID-19 case, COVID-19 infections, complex, cardiometabolic risk factor, covariate, risk reduction, drug regimens, Effects, approach, data-driven, statistical, highlight, initial, collected, develop, investigated, the disease, applied, hospitalized patient, reducing, correlated, to define, patients hospitalized, Significance, with COVID-19, 【제목키워드】 risk, drug, Protective, profile, approach, data-driven, identify,